Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Clinical Trial Evaluating the Safety and Efficacy of the Combination of Nintedanib+Tocilizumab Compared to Standard Treatment in Patients With Systemic Sclerosis and Interstitial Lung Disease. Analysis With Theranostic Approach

NCT06297096 is registered in ClinicalTrials.gov with National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland as lead sponsor.

NCT NCT06297096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06297096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Clinical Trial Evaluating the Safety and Efficacy of the Combination of Nintedanib+Tocilizumab Compared to Standard Treatment in Patients With Systemic Sclerosis and Interstitial Lung Disease. Analysis With Theranostic Approach
Lead sponsor
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Phase
Phase 3
Overall status
Recruiting
Start date
July 1, 2025
Completion date
March 30, 2028
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, systemic sclerosis